Stay updated with breaking news from Mark Litton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
16.11.2022 - Fosgonimeton treatment showed results suggestive of neuroprotection and potential disease modification in models of Parkinson’s disease Small molecule positive modulators of HGF/MET improved symptoms of diabetic neuropathy with a persistent ... Seite 1
PHILADELPHIA, Oct. 16, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (“Athira” or the “Company”)...
Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...
Additional data showed numerical improvement in activities of daily living , a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a pre-specified... | August 3, 2022
An Alzheimer’s disease drug from Athira Pharma has failed a Phase 2 clinical trial and the biotech has a surprising theory why. Athira says standard of care drugs Alzheimer’s patients are already taking may diminish the effect of its small molecule and this finding could inform how the company proceeds with an ongoing Phase 3 clinical trial.